Migraitan tablets 50mg Migraine Relief - 2 tablets

Please note images are for illustration purposes and may differ from the product(s) you receive
  • Fast acting
  • Relieves symptoms of throbbing pain in head, nausea and sensitivity to sound and light.
Single purchase only
Subscribe and save
  • Fast acting
  • Relieves symptoms of throbbing pain in head, nausea and sensitivity to sound and light.
Free Delivery Truck IconFREE DELIVERY on UK orders over £15. Read more...
Product Information
Migraitan is a film-coated tablet containing Sumatriptan 50mg. It's aim is to quickly alleviate migraine symptoms such as throbbing pain in the head, nausea and sensitivity to sound and light.

Migraitan contains the active substances called sumatriptan. Migraitan is indicated for the acute intermittent treatment of migraine. It should not be used prophylactically.
The recommended dose of Migraitan should not be exceeded.
It is advisable that Migraitan be taken as early as possible after the onset of a migraine attack but it is equally effective at whatever stage of the attack it is administered.
The recommended dose of oral Migraitan is a one 50mg tablet.
Some patients may require 100mg.
If the patient has responded to the first dose but the symptoms recur, a second dose may be taken provided that there is a minimum interval of 2 hours between the two doses.
No more than two 50 mg tablets (total dose 100mg) may be taken in any 24 hour period or to treat the same attack.
Each film-coated tablet contains Sumatriptan succinate equivalent to 50mg sumatriptan.
List of excipients:Lactose monohydrate,Microcrystalline cellulose, Pregelatinised starch, Croscarmellose sodium, Magnesium stearate, Hypromellose, Titanium dioxide E171, Purified talc, Macrogol, Iron oxide red E172, Iron oxide yellow E172
Suitable For
Not suitable for those under the age of 18 or over the age of 65.
Only suitable for patients who have been previously diagnosed by a doctor or pharmacist with migraines.
Following administration, sumatriptan can be associated with transient symptoms including chest pain and tightness which may be intense and involve the throat. Where such symptoms are thought to indicate ischaemic heart disease, no further doses of sumatriptan should be given and appropriate evaluation should be carried out.
Sumatriptan should not be given to patients with risk factors for ischaemic heart disease, including those patients who are heavy smokers or users of nicotine substitution therapies, without prior cardiovascular evaluation
Keep out of sight and reach of children.
Frequently Asked Questions (0)